Mechanisms and Biomarkers of Successful Allergen-specific Immunotherapy

Overview

Journal Asia Pac Allergy

Publisher Wolters Kluwer

Date 2022 Dec 1

PMID 36452016

Authors

Juan-Felipe Lopez

Manal Bel Imam

Pattraporn Satitsuksanoa

Sophieke Lems

Minglin Yang

Yu-Kyoung Hwang

Purevsuren Losol

Jun-Pyo Choi

Sae-Hoon Kim

Yoon-Seok Chang

Mubeccel Akdis

Cezmi A Akdis

Willem van de Veen

Affiliations

Soon will be listed here.

Abstract

Allergen-specific immunotherapy (AIT) is considered the only curative treatment for allergic diseases mediated by immunoglobulin E (IgE). Currently, the route of administration depends both on the different types of causal allergens and on its effectiveness and safety profile. Several studies have reported the mechanisms and changes in humoral and cellular response underlying AIT; however, the full picture remains unknown. Knowledge of who can benefit from this type of treatment is urgently needed due to the patient safety risks and costs of AIT. or biomarkers have become a strategy to predict clinical outcomes in precision medicine. There are currently no standardized biomarkers that allow determining successful responses to AIT, however, some studies have found differences between responders and nonresponders. In addition, different candidates have been postulated that may have the potential to become biomarkers. In this review, we aim to summarize the findings to date related to biomarkers in different IgE-mediated allergic diseases (respiratory, food, and venom allergy) with the potential to define who will benefit from AIT.

Citing Articles

Allergen-specific B cell responses in oral immunotherapy-induced desensitization, remission, and natural outgrowth in cow's milk allergy.

Satitsuksanoa P, Veen W, Tan G, Lopez J, Wirz O, Jansen K Allergy. 2024; 80(1):161-180.

PMID: 38989779 PMC: 11724240. DOI: 10.1111/all.16220.

Potential Effects of AIT on Nonspecific Allergic Immune Responses or Symptoms.

Nakagome K, Fujio K, Nagata M J Clin Med. 2023; 12(11).

PMID: 37297972 PMC: 10253781. DOI: 10.3390/jcm12113776.

: Asia Pacific and beyond.

Chang Y Asia Pac Allergy. 2022; 12(4):e46.

PMID: 36452010 PMC: 9669472. DOI: 10.5415/apallergy.2022.12.e46.

References

Wen Y, Zhou L, Li Y, Li Z, Deng W, Zhang T . Role of leptin in allergic rhinitis during sublingual immunotherapy. Eur Arch Otorhinolaryngol. 2018; 275(11):2733-2738. DOI: 10.1007/s00405-018-5123-0. View

Kulis M, Smeekens J, Burk C, Yue X, Guo R, Orgel K . Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy. J Allergy Clin Immunol. 2022; 150(5):1144-1153. PMC: 9643597. DOI: 10.1016/j.jaci.2022.05.020. View

Feindor M, Heath M, Hewings S, Carreno Velazquez T, Blank S, Grosch J . Venom Immunotherapy: From Proteins to Product to Patient Protection. Toxins (Basel). 2021; 13(9). PMC: 8470233. DOI: 10.3390/toxins13090616. View

Kauppila T, Hinkkanen V, Savinko T, Karisola P, Kukkonen A, Paassilta M . Long-term changes in milk component immunoglobulins reflect milk oral immunotherapy outcomes in Finnish children. Allergy. 2022; 78(2):454-463. PMC: 10087274. DOI: 10.1111/all.15479. View

Yao Y, Wang N, Chen C, Pan L, Wang Z, Yunis J . CD23 expression on switched memory B cells bridges T-B cell interaction in allergic rhinitis. Allergy. 2020; 75(10):2599-2612. DOI: 10.1111/all.14288. View

Lue K, Lin Y, Sun H, Lu K, Hsieh J, Chou M . Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006; 17(6):408-15. DOI: 10.1111/j.1399-3038.2006.00443.x. View

Schmid J, Wurtzen P, Siddhuraj P, Jogdand P, Petersen C, Dahl R . Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. Allergy. 2020; 76(5):1528-1538. DOI: 10.1111/all.14264. View

Globinska A, Boonpiyathad T, Satitsuksanoa P, Kleuskens M, Veen W, Sokolowska M . Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens. Ann Allergy Asthma Immunol. 2018; 121(3):306-312. DOI: 10.1016/j.anai.2018.06.026. View

Schuerwegh A, De Clerck L, Bridts C, Stevens W . Wasp venom immunotherapy induces a shift from IL-4-producing towards interferon-gamma-producing CD4+ and CD8+ T lymphocytes. Clin Exp Allergy. 2001; 31(5):740-6. DOI: 10.1046/j.1365-2222.2001.01066.x. View

10.

Wahn U, Bachert C, Heinrich J, Richter H, Zielen S . Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2018; 74(3):594-604. PMC: 6585786. DOI: 10.1111/all.13598. View

11.

Eifan A, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler N . Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010; 40(6):922-32. DOI: 10.1111/j.1365-2222.2009.03448.x. View

12.

Kemeny D, Lessof M, Patel S, Youlten L, Williams A, Lambourn E . IgG and IgE antibodies after immunotherapy with bee and wasp venom. Int Arch Allergy Appl Immunol. 1989; 88(1-2):247-9. DOI: 10.1159/000234799. View

13.

Muller U, Helbling A, Berchtold E . Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992; 89(2):529-35. DOI: 10.1016/0091-6749(92)90319-w. View

14.

Su W, Zhong W, Zhang Y, Xia Z . Synthesized OVA323-339MAP octamers mitigate OVA-induced airway inflammation by regulating Foxp3 T regulatory cells. BMC Immunol. 2012; 13:34. PMC: 3472185. DOI: 10.1186/1471-2172-13-34. View

15.

Lockey R, Turkeltaub P, Olive E, Hubbard J, BUKANTZ S . The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol. 1990; 86(5):775-80. DOI: 10.1016/s0091-6749(05)80182-4. View

16.

Caruso M, Cibella F, Emma R, Campagna D, Tringali G, Amaradio M . Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis. Int Immunopharmacol. 2018; 60:50-58. DOI: 10.1016/j.intimp.2018.04.034. View

17.

Fan D, Wang X, Wang C, Wang Y, Cao F, Zhang L . Suppression of Immunotherapy on Group 2 Innate Lymphoid Cells in Allergic Rhinitis. Chin Med J (Engl). 2016; 129(23):2824-2828. PMC: 5146790. DOI: 10.4103/0366-6999.194642. View

18.

Wright B, Kulis M, Orgel K, Burks A, Dawson P, Henning A . Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness. Allergy. 2016; 71(11):1552-1560. PMC: 5035709. DOI: 10.1111/all.12895. View

19.

Wang S, Xia P, Chen Y, Qu Y, Xiong Z, Ye B . Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. Cell. 2017; 171(1):201-216.e18. DOI: 10.1016/j.cell.2017.07.027. View

20.

Patil S, Steinbrecher J, Calatroni A, Smith N, Ma A, Ruiter B . Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy. J Allergy Clin Immunol. 2019; 144(5):1310-1319.e4. PMC: 6905043. DOI: 10.1016/j.jaci.2019.07.028. View